subscribeSubscribe
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat)

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat)
GLOBENEWSWIRE
28 Sep 2022
Share Share
Cornerstone Pharma to Present Data on CPI-613 From Open-Label PI Study at ESMO

Cornerstone Pharma to Present Data on CPI-613 From Open-Label PI Study at ESMO
GLOBENEWSWIRE
27 Jun 2022
Share Share
Cornerstone Pharma Announces Published Data on CPI-613 as an Effective Approach

Cornerstone Pharma Announces Published Data on CPI-613 as an Effective Approach
GLOBENEWSWIRE
16 Jun 2022
Share Share
EMA Grants ODD to Cornerstone`s CPI-613 (Devimistat) for Biliary Tract Cancer

EMA Grants ODD to Cornerstone`s CPI-613 (Devimistat) for Biliary Tract Cancer
GLOBENEWSWIRE
24 May 2022
Share Share
Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer

Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer
GLOBENEWSWIRE
18 Jan 2022
Share Share
Rafael Pharma Completes Dose Escalation in APOLLO 613 Phase 1/2 Trial of CPI-613

Rafael Pharma Completes Dose Escalation in APOLLO 613 Phase 1/2 Trial of CPI-613
GLOBENEWSWIRE
06 Jan 2022
Share Share
Rafael Begins Enrollment in Phase 1/2 Trial of CPI-613 in Clear Cell Sarcoma

Rafael Begins Enrollment in Phase 1/2 Trial of CPI-613 in Clear Cell Sarcoma
GLOBENEWSWIRE
11 Nov 2021
Share Share
Telecom tycoon`s phase 3 pancreatic cancer bet flames out

Telecom tycoon`s phase 3 pancreatic cancer bet flames out
Michael Dabaie MARKETWATCH
29 Oct 2021
Share Share
Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials

Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials
GLOBENEWSWIRE
28 Oct 2021
Share Share
Rafael Announces Positive Data on (ARMADA 2000) of CPI-613

Rafael Announces Positive Data on (ARMADA 2000) of CPI-613
GLOBENEWSWIRE
01 Jul 2021
Share Share